Hospital-Administered Antibiotics Linked to Sepsis Risk
By HospiMedica International staff writers Posted on 08 Nov 2016 |
Exposure to antibiotics that disturb the healthy microbiome during a hospital stay can sharply increase the risk of sepsis or septic shock after discharge, according to a new study.
Researchers at the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) conducted a retrospective cohort study of the Truven Health MarketScan hospital drug database, which includes demographic, treatment, and hospital admission and discharge data; the database also includes pharmacy data, making it possible to track antibiotic use. The researchers obtained data on 12.7 million hospital stays in 516 U.S. facilities between 2006 and 2010, including 18,307 stays that were associated with sepsis admission within 90 days of discharge.
The researchers then defined a list of antibiotics with a high risk of disturbing the microbiome, including third- or fourth-generation cephalosporins, fluoroquinolones, lincosamides, beta-lactam/beta-lactamase inhibitor combinations, oral vancomycin, and carbapenems. Earlier cephalosporins, tetracycline, and sulfa drugs were regarded as low-risk, while control antibiotics, such as penicillin, were thought to have limited potential to disrupt the microbiome. The primary endpoint was the risk of sepsis following use of those drugs, compared with no antibiotic use.
The results showed that in 43% of the hospital stays, patients had not been given any antibiotics, while patients got high-, low-, and no-risk drugs in 28%, 24%, and 5% of the stays, respectively. Upon analysis, the odds ratio for sepsis was 1.78 following high-risk drugs, 1.1 following low-risk drugs, and 1.22 after no-risk drugs. Duration of therapy also played a role; regardless of drug type, patients treated for more than 14 days had twice the risk of later sepsis as those given shorter therapy, with an odds ratio of 2.4. The study was presented at the annual IDWeek meeting, held during October 2016 in New Orleans (LA, USA).
“Environmental exposures, such as antibiotics, can lead to a shift in the microbiome with great pathogenic potential. The exact mechanisms remain under investigation,” said lead author James Baggs, PhD, of the CDC. “The study contributes to the growing body of observational evidence and animal data that antibiotics can have broad detrimental effects. Physicians and health authorities have one preventive measure that's currently available - improved antibiotic stewardship.”
IDWeek brings together four organizations that focus on infectious disease – the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).
Related Links:
U.S. Centers for Disease Control and Prevention
Researchers at the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) conducted a retrospective cohort study of the Truven Health MarketScan hospital drug database, which includes demographic, treatment, and hospital admission and discharge data; the database also includes pharmacy data, making it possible to track antibiotic use. The researchers obtained data on 12.7 million hospital stays in 516 U.S. facilities between 2006 and 2010, including 18,307 stays that were associated with sepsis admission within 90 days of discharge.
The researchers then defined a list of antibiotics with a high risk of disturbing the microbiome, including third- or fourth-generation cephalosporins, fluoroquinolones, lincosamides, beta-lactam/beta-lactamase inhibitor combinations, oral vancomycin, and carbapenems. Earlier cephalosporins, tetracycline, and sulfa drugs were regarded as low-risk, while control antibiotics, such as penicillin, were thought to have limited potential to disrupt the microbiome. The primary endpoint was the risk of sepsis following use of those drugs, compared with no antibiotic use.
The results showed that in 43% of the hospital stays, patients had not been given any antibiotics, while patients got high-, low-, and no-risk drugs in 28%, 24%, and 5% of the stays, respectively. Upon analysis, the odds ratio for sepsis was 1.78 following high-risk drugs, 1.1 following low-risk drugs, and 1.22 after no-risk drugs. Duration of therapy also played a role; regardless of drug type, patients treated for more than 14 days had twice the risk of later sepsis as those given shorter therapy, with an odds ratio of 2.4. The study was presented at the annual IDWeek meeting, held during October 2016 in New Orleans (LA, USA).
“Environmental exposures, such as antibiotics, can lead to a shift in the microbiome with great pathogenic potential. The exact mechanisms remain under investigation,” said lead author James Baggs, PhD, of the CDC. “The study contributes to the growing body of observational evidence and animal data that antibiotics can have broad detrimental effects. Physicians and health authorities have one preventive measure that's currently available - improved antibiotic stewardship.”
IDWeek brings together four organizations that focus on infectious disease – the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).
Related Links:
U.S. Centers for Disease Control and Prevention
Latest Critical Care News
- Transcatheter Valve Replacement Outcomes Similar To Surgery, Finds Study
- Revascularization Improves Life Quality in Chronic Limb-Threatening Ischemia, Finds Study
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women